Bacterial | Page 24 of 28 | SpiritIndia.com

Health :: Staph Vaccine Shows Promise in Staphylococcus infections

By combining four proteins of Staphylococcus aureus that individually generated the strongest immune response in mice, scientists have created a vaccine that significantly protects the animals from diverse strains of the bacterium that cause disease in humans. A report describing the University of Chicago study, funded by the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health, appears online this week in the Proceedings of the National Academy of Sciences.

Sinusitis :: New, minimally invasive surgery to treat sinusitis

If drug therapy can’t open blocked sinuses, sufferers now have a novel option. Mayo Clinic ear, nose and throat (ENT) surgeons have taken a page from the book of cardiology in performing a new, outpatient procedure to alleviate acute or chronic symptoms of sinusitis, an inflammation of the sinus cavities usually due to an infection.

Bronchiolitis :: Antibiotics, steroids, or bronchodilators to treat bronchiolitis not required

In a new clinical practice guideline, the American Academy of Pediatrics (AAP) outlines recommendations for diagnosing and managing bronchiolitis, the most common lower respiratory infection in children under age 2. The symptoms of bronchiolitis often mirror those of asthma or bacterial pneumonia, resulting in misdiagnosis and incorrect treatment.

Tuberculosis :: A large, untapped global market exists for improved TB tests

A significant and largely untapped global market exists for more effective and affordable tests to diagnose tuberculosis in low and middle income countries, where most TB cases today occur.

Tooth Decay :: New Weapon in Fight Against Tooth Decay

A group of scientists representing the UCLA School of Dentistry; the UCLA Department of Microbiology, Immunology and Molecular Genetics, and C3 Jian Corporation have succeeded in creating a pheromone-guided “smart” anti-microbial peptide capable of selectively eliminating Streptococcus mutans, a leading bacterial cause of tooth decay, in 30 seconds.

Dental Health :: Promising Approach to Prevent Tooth Decay

Preventing cavities could one day involve the dental equivalent of a military surgical strike. A team of researchers supported by the National Institute of Dental and Craniofacial Research report they have created a new smart anti-microbial treatment that can be chemically programmed in the laboratory to seek out and kill a specific cavity-causing species of bacteria, leaving the good bacteria untouched.

Meningitis :: Meningitis shot and risk for Guillain Barre syndrome

Young people who get a new meningitis shot may be at a slightly higher risk of developing a paralyzing side effect, federal researchers said. Even so, U.S. health officials said the benefits far outweigh the risk of getting the rare condition, Guillain Barre syndrome. They are not backing off their recommendation that most students be vaccinated.

Dental Health :: Oragenics reports positive clinical results with its oral probiotic mouthrinse

Oragenics, Inc. (Amex: ONI) announced today that the first of two sets of subjects has completed a clinical trial utilizing its proprietary oral probiotic product, Probiora3(TM). The trial was designed to determine safety and the effectiveness of the mouthrinse against baseline levels of disease-causing bacteria in the mouth. Daily mouth rinsing with Probiora3(TM) resulted in substantial reductions in the numbers of the bacterium, S. mutans, which attacks teeth, as well as two target periodontal strains, Porphyromonas gingivalis and Campylobacter rectus, associated with gum disease and bad breath. The product was well tolerated by the subjects and no safety issues were identified with the twice daily use of the product over a two-month period.

Allergy :: Food allergies could be fought with friendly bacteria in alcoholic milkshake

Feeding babies alcoholic milk may help to protect against some food allergies. Kefir, a traditional fermented drink, is consumed in Eastern Europe as a health food, and is often used to wean babies, as it is easily digested. Food allergy prevalence is especially high in children under the age of three, with around 5-8% of infants at risk. Currently the only treatment is avoidance of the problematic food.

Smoking :: Nabi biopharmaceuticals completes enrollment in nicvax phase iib ‘proof-of-concept’ clinical trial

Nabi Biopharmaceuticals (Nasdaq: NABI) today announced it has completed enrollment for its Phase IIB “proof-of-concept” study for NicVAX(R) (Nicotine Conjugate Vaccine), the company’s novel, innovative and proprietary investigational vaccine being developed to treat nicotine addiction and prevent smoking relapse. Enrollment for the trial was completed three months earlier than anticipated, paving the way for the release of trial results early in the second quarter of 2007.